» Articles » PMID: 17893275

Disruption of Type 5 Adenylyl Cyclase Enhances Desensitization of Cyclic Adenosine Monophosphate Signal and Increases Akt Signal with Chronic Catecholamine Stress

Overview
Journal Circulation
Date 2007 Sep 26
PMID 17893275
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Desensitization of the cyclic adenosine monophosphate signal protects cardiac myocytes against catecholamine stress, thus preventing the development of apoptosis. Molecular mechanisms of desensitization have been well studied at the level of adrenergic receptors but less so at the level of the effector enzyme, adenylyl cyclase (AC).

Methods And Results: When the effects of long-term (1 to 2 weeks) isoproterenol infusion were compared between type 5 AC-null mice (AC5KO) and wild-type controls, we found that the subsequent responses of left ventricular ejection fraction to sudden intravenous isoproterenol challenge were reduced in AC5KO compared with wild-type mice (ie, physiological desensitization was more effective in AC5KO), consistent with enhanced downregulation of AC catalytic activity in AC5KO. One mechanism for the less effective desensitization in wild-type mice was paradoxical upregulation of type 5 AC protein expression. The number of apoptotic myocytes was similar at baseline but was significantly less in AC5KO after infusion. This was accompanied by a 4-fold greater increase in Bcl-2 and a 3-fold greater increase in phospho-Akt in AC5KO. The latter is most likely mediated by increased membrane localization of phosphoinositide-dependent protein kinase 1, which is known to be inhibited by the cyclic adenosine monophosphate signal.

Conclusions: The absence of type 5 AC results in more effective desensitization after long-term catecholamine stress and protects against the development of myocyte apoptosis and deterioration of cardiac function, potentially elucidating a novel approach to the therapy of heart failure.

Citing Articles

Nanodomain cAMP signaling in cardiac pathophysiology: potential for developing targeted therapeutic interventions.

Zaccolo M, Kovanich D Physiol Rev. 2024; 105(2):541-591.

PMID: 39115424 PMC: 7617275. DOI: 10.1152/physrev.00013.2024.


Dysfunctional mitochondria elicit bioenergetic decline in the aged heart.

Mone P, Agyapong E, Morciano G, Jankauskas S, De Luca A, Varzideh F J Cardiovasc Aging. 2024; 4(2).

PMID: 39015481 PMC: 11250775. DOI: 10.20517/jca.2023.50.


Adenylyl cyclase isoforms 5 and 6 in the cardiovascular system: complex regulation and divergent roles.

Maghsoudi S, Shuaib R, Van Bastelaere B, Dakshinamurti S Front Pharmacol. 2024; 15:1370506.

PMID: 38633617 PMC: 11021717. DOI: 10.3389/fphar.2024.1370506.


Effects of the angiotensin-converting enzyme inhibitor captopril on occlusal-disharmony-induced cardiac dysfunction in mice.

Ito A, Ohnuki Y, Suita K, Matsuo I, Ishikawa M, Mitsubayashi T Sci Rep. 2023; 13(1):19927.

PMID: 37968296 PMC: 10651878. DOI: 10.1038/s41598-023-43099-6.


Role of cAMP in Cardiomyocyte Viability: Beneficial or Detrimental?.

Zhang Y, Chen S, Luo L, Greenly S, Shi H, Xu J Circ Res. 2023; 133(11):902-923.

PMID: 37850368 PMC: 10807647. DOI: 10.1161/CIRCRESAHA.123.322652.